Skip to content

Effects of an AI-Enabled Multi-Component Intervention on Adherence to Colorectal Cancer Screening: A Multicenter Cluster Randomized Controlled Trial

Development and Application of Key Technologies for Precision Prevention and Control of Colorectal Cancer and an Intelligent End-to-End Management System

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128638
Enrollment
Unknown
Registered
2026-07-23
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Intervention group:AI-based comprehensive digital intervention
Control group:Usual care

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Permanent local residents aged 40–74 years; 2. No prior diagnosis of colorectal cancer; 3. Own a smartphone with access to WeChat and ability to operate smart devices; 4. Willing and able to sign (or electronically confirm) informed consent.

Exclusion criteria

Exclusion criteria: 1. History of colorectal cancer; 2. Prior colorectal resection surgery; 3. Currently receiving any cancer-related treatment (excluding non-melanoma skin cancer); 4. Undergone colonoscopy, flexible sigmoidoscopy, CT colonography, or double-contrast barium enema within the past 5 years; 5. Undergone fecal occult blood test or fecal DNA test within the past 1 year; 6. Presence of symptomatic lower gastrointestinal disease or symptoms warranting diagnostic colonoscopy, including: hematochezia lasting for an extended period within the past 6 months; 1. medically diagnosed iron deficiency anemia; 2. documented unexplained weight loss (>10% of baseline body weight) within the past 6 months; 7. Other severe comorbidities that may reduce screening benefit or increase the risk of colonoscopy (including severe pulmonary disease, advanced kidney disease, advanced liver disease, severe heart failure, or a recent diagnosis of cancer other than non-melanoma skin cancer); 8. Cognitive impairment or psychiatric disorders that prevent understanding and compliance with the study procedures.

Design outcomes

Primary

MeasureTime frame
Overall compliance with colorectal cancer screening;

Secondary

MeasureTime frame
Acceptability;Changes in screening willingness;The initial screening completion rate;Colonoscopy adherence after any positive screening result;Changes in screening awareness and health beliefs;Feasibility;

Countries

China

Contacts

Public ContactDai Min

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

daimin2002@hotmail.com+86 10 87787428

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026